Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 18/20 | 0.75 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.50 |
| ▸ | EBP | Q15125 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5852716 | 1.00 | ESR1 (0.75) | ESR1ESR2EBPSIGMAR1 | |
| SCHEMBL5851575 | 0.99 | ESR1 (0.77) | ESR1ESR2EBPSIGMAR1 | |
| SCHEMBL5851524 | 0.95 | ESR1 (0.77) | ESR1ESR2EBPSIGMAR1 | |
| SCHEMBL5851829 | 0.92 | ESR1 (0.72) | ESR1ESR2EBPSIGMAR1 | |
| SCHEMBL5852061 | 0.92 | ESR1 (0.72) | ESR1ESR2EBPSIGMAR1 | |
| SCHEMBL5851677 | 0.91 | ESR1 (0.74) | ESR1ESR2EBPSIGMAR1 | |
| SCHEMBL5852820 | 0.90 | ESR1 (0.70) | ESR1ESR2EBPSIGMAR1 | |
| SCHEMBL5851569 | 0.88 | ESR1 (0.77) | ESR1ESR2EBPSIGMAR1 | |
| SCHEMBL5078326 | 0.87 | ESR1 (0.69) | ESR1ESR2EBPSIGMAR1 | |
| SCHEMBL5851849 | 0.87 | ESR1 (0.55) | ESR1ESR2EBPSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7321044-B2 | Synthesis of oxygen-substituted benzocycloheptenes as valuable intermediate products for the production of tissue-selective estrogens | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-01-22 | — | — | US | disclosed |
| US-7321044-B2 | Synthesis of oxygen-substituted benzocycloheptenes as valuable intermediate products for the production of tissue-selective estrogens | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-01-22 | — | — | US | disclosed |
| US-7321044-B2 | Synthesis of oxygen-substituted benzocycloheptenes as valuable intermediate products for the production of tissue-selective estrogens | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-01-22 | — | — | US | disclosed |
| US-7145015-B2 | Benzocycloheptenes, process for their production, pharmaceutical preparations that contain that latter as well as their use for the production of pharmaceutical agents | SCHERING AG (DE) | 2006-12-05 | — | — | US | disclosed |
| US-20050182081-A1 | Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-08-18 | — | — | US | disclosed |
| US-6878750-B2 | Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents | SCHERING AG (DE) | 2005-04-12 | — | — | US | disclosed |
| EP-1436254-A1 | SYNTHESIS OF OXYGEN-SUBSTITUTED BENZOCYCLOHEPTENES, USED AS VALUABLE INTERMEDIATE PRODUCTS FOR PRODUCING TISSUE-SELECTIVE OESTROGENS | Schering Aktiengesellschaft (DE) | 2004-07-14 | — | — | EP | disclosed |
| US-20030162974-A1 | Synthesis of oxygen-substituted benzocycloheptenes as valuable intermediate products for the production of tissue-selective estrogens | SCHERING AG (DE) | 2003-08-28 | — | — | US | disclosed |
| EP-1098874-B1 | BENZOCYCLOHEPTENES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS, AND THEIR USE FOR PRODUCING MEDICAMENTS | SCHERING AG (DE) | 2003-06-18 | — | — | EP | disclosed |
| WO-2003033461-A1 | SYNTHESIS OF OXYGEN-SUBSTITUTED BENZOCYCLOHEPTENES, USED AS VALUABLE INTERMEDIATE PRODUCTS FOR PRODUCING TISSUE-SELECTIVE OESTROGENS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-24 | — | — | WO | disclosed |
| US-20030050324-A1 | Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents | SCHERING AG (DE) | 2003-03-13 | — | — | US | disclosed |
| US-6495607-B2 | 8,9-DIHYDRO-7H-BENZOCYCLOHEPTENE DERIVATIVES ARE USEFUL FOR PHOPHYLAXIS AND THERAPY OF OSTEOPOROSIS(HAVE SELECTIVE ESTROGENIC ACTIVITY ON BONES) | SCHERING AG (DE) | 2002-12-17 | — | — | US | disclosed |
| US-20020068765-A1 | BENZOCYCLOHEPTENES, PROCESS FOR THEIR PRODUCTION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THE LATTER AS WELL AS THEIR USE FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2002-06-06 | — | — | US | disclosed |
| EP-1098874-A1 | BENZOCYCLOHEPTENES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS, AND THEIR USE FOR PRODUCING MEDICAMENTS | Schering Aktiengesellschaft (DE) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000003979-A1 | BENZOCYCLOHEPTENES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS, AND THEIR USE FOR PRODUCING MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068765-A1 | BENZOCYCLOHEPTENES, PROCESS FOR THEIR PRODUCTION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THE LATTER AS WELL AS THEIR USE FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS | CYP19A1, ESRRA, SULT2A1 | ESR1 36/4885ESR2 5/4885EBP 92/4885 |
| US-20050182081-A1 | Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents | CYP19A1, ESR2, ESRRA | ESR1 8/4885ESR2 2/4885EBP 62/4885 |
| US-20030162974-A1 | Synthesis of oxygen-substituted benzocycloheptenes as valuable intermediate products for the production of tissue-selective estrogens | CYP19A1, HSD17B11, SULT1E1 | ESR1 6/4885ESR2 9/4885EBP 145/4885 |
| US-20030050324-A1 | Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents | CYP19A1, ESRRA, SULT2A1 | ESR1 36/4885ESR2 5/4885EBP 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.